The GCMI 2023 State of Medtech Design and Development Report: Part 1

Innovation in medical technologies is something of a paradox. On one hand, new technologies that drive innovation can manifest at breakneck speed. On the other hand, the pace at which those technologies breed innovations that reach full commercialization and patient impact can be glacial by comparison.   What have been the most significant changes with…

GCMI CEO Sherry Farrugia Named to Inaugural Atlanta Business Chronicle “Power 10 in Health Care”

GCMI team members continue to distinguish themselves through industry association or other external recognition. Very recently this was the case for our CEO Sherry Farrugia who was named to the inaugural Atlanta Business Chronicle “Power 10: Health Care list.”   From the publication: “​​There is no shortage of exceptional health care professionals in metro Atlanta.…

What do pediatric innovators need to know about risk, regulatory, IP and more for new pediatric technologies? A Pediatric Tech Talk recording.

Innovation in pediatric technologies that address unmet clinical needs lags behind innovation for adult populations in large part due to its relatively small market size and ROI (return on investment) prospects for industry, continuously changing anatomies of children, and limited populations for testing and clinical trials.   Activity sequence and process matters a great deal…

THE Place to Start, And Follow-On, For University-Sourced Medtech Innovation Funding

A dive into the Georgia Research Alliance (GRA) and its funding programs with GRA VP of Venture Development Ashley Cornelison In the first of this short series on medtech innovation funding opportunities, GCMI Director of Scientific Affairs Evan Goldberg stated, “GRA is the first place to go for those trying to commercialize a technology out…

The Top Five Medtech and Life Science Funding Sources for GT Faculty, Researchers, Investigators – AT PHASE ZERO

Atlanta is a burgeoning center of medtech and life science innovation. Georgia Tech faculty, researchers and students are measurable contributors to that ecosystem.   Medtech innovation and the commercialization that creates real impact in provision of care, improved outcomes and value is replete with requirements and pitfalls that can doom ideas and technologies with high…

It’s About Time! 2023 BME Spring Capstone Team Aims to Reduce 70% Failure Rate of Common Lumbar Punctures

Lumbar punctures are a procedure performed by neurologists to obtain cerebrospinal fluid from a patient’s back, typically from the L3/L4 spinal canal, and are used for diagnosis and treatment of many neurological diseases and cancers. There are more than 8 million conducted worldwide every year, including 370,000 in the United States.   Currently, doctors feel…

Reducing the 90% Recurrence Rate for Glioblastoma Treatment Through an Implantable Device for the Delivery of Stem Cells

GCMI’s Spring 2023 Capstone Spotlight on Team LifeSTEM “Gliomas are brain tumors that come in multiple forms ranging from low-grade, benign tumors to high-grade, malignant tumors including glioblastomas. Glioblastoma treatment involves surgical resection, chemotherapy, and radiation. However, these tumors are typically incompletely resected, so there is a 90% recurrence rate [for a course of treatment,…

When ROI Gets Squeezed By Market Size, Process In Medtech Innovation Means Even More

Revolutionizing Pediatrics: Innovations in Medical Device Design & Development. A Pediatric Tech Talk Webinar with GCMI, June 21, 2023 – 12:00 p.m. Eastern   “Innovation in pediatric technologies that address unmet clinical needs lags behind innovation for adult populations in large part due to its relatively small market size and ROI (return on investment) prospects…

Taking a Bite Out of a 9.5% ORIF Re-Operation Rate

“X-rays supporting our testing at GCMI and T3 Labs clearly showed where the device engaged and the tip aligned at the bone level. This kind of evidence is important for our design history file, something that should make our regulatory journey and overall commercialization pathway more efficient.”